Significantly
clearer skin
6x more patients who received VTAMA cream achieved treatment success* vs vehicle, with significant results as early as week 4.2,5-7
PGA treatment success: PGA score of 0 or 1 and ≥2-grade improvement from baseline to week 12 (ITT, MI)2,5-7
36% and 40% of patients achieved treatment success in the VTAMA cream arms vs 6% and 6% in the vehicle arms in PSOARING 1 and 2.2
PASI75 from baseline to week 12 (ITT, MI)5,8
VTAMA cream delivered significant PASI75 rates as early as week 4 and at week 12, up to 48% of patients achieved PASI75 vs ~10% of those using vehicle.
ITT, intention-to-treat; MI, multiple imputation; PASI75, ≥75% improvement in Psoriasis Area and Severity Index; PGA, Physician Global Assessment.
Remittive effect is continued efficacy while on treatment and lasting results even when off-treatment as demonstrated in the 40-week, open-label, long-term extension study (LTE).3
Not actual patients
Patients (n=73) who entered the open-label LTE with clear skin (PGA=0) maintained clear or almost clear skin (PGA=0 or 1) for a median time of 114 days2
Of the patients (n=519) entering the open-label LTE with PGA≥2, 58.2% achieved PGA=0 or 1 at least once during the open-label LTE3
No evidence of tachyphylaxis3
PSOARING 3 was an open-label, long-term extension study (LTE) designed to evaluate safety, durability of response, and duration of remittive effect (median time to PGA≥2 from PGA=0) of VTAMA cream over 40 weeks.3
763 patients enrolled
At the end of the 12-week pivotal studies, 763 patients (92% of eligible patients) rolled over to the open-label LTE2,3
Clear skin
41% of patients (n=312) achieved PGA=0 at least once during the open‑label LTE and had a mean total duration of disease control (PGA=0 or 1) of ~4 months3
~4 Months off-treatment
Patients (n=73) entering the open‑label LTE with clear skin (PGA=0) maintained clear or almost clear skin (PGA=0 or 1) for a median time of 114 days2
Sign up today to get the latest around VTAMA (tapinarof) cream, 1%, and other helpful tips and information.
*Required field
When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer.
|
Always active |
|
|
|
Robert, 36
Not an actual patient
Your adventurous patient
• Concerned about plaque psoriasis flare-ups limiting his active lifestyle. During a flare-up, his affected BSA can go up to 5% and his PGA score is 3 (moderate)
• Wants something to help keep his psoriasis plaques clearer so he doesn’t have to worry about them
Emily, 51
Not an actual patient
Your active and public‑facing patient
• Works in a public-facing job and is self-conscious about her appearance when having a plaque psoriasis flare
• Has mild plaque psoriasis and is not a candidate for biologics
• Cycled through different over-the-counter steroid creams, which did not give her the results she was looking for
• Does a lot of research but relies on her dermatologist for her best options
Carlos, 55
Not an actual patient
Your patient with sensitive skin
• Has an affected BSA of 10%, and psoriasis plaques are concentrated in sensitive areas
• Has psoriasis plaques on sensitive areas of his body, including his genitals, causing embarrassment
• Felt topical corticosteroids were not the right option for him due to his treatment area
• Wants to get back to socializing and dating without worrying about psoriasis plaques